Changeflow GovPing Pharma & Drug Safety Mammalian Cell SHMT2 Reduction for Protein Prod...
Routine Notice Added Final

Mammalian Cell SHMT2 Reduction for Protein Production

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

USPTO published patent application US20260098081A1 disclosing isolated mammalian cells with reduced or eliminated SHMT2 expression and methods for using such cells in recombinant protein production. The application names Samuel Peters, James Ravellette, David Razafsky, Jason A. Gustin, and Trissa Borgschulte as inventors. Filing date was September 29, 2023, under application number 19112697.

What changed

USPTO published patent application US20260098081A1 disclosing isolated mammalian cells with reduced or eliminated Serine Hydroxymethyltransferase 2 (SHMT2) expression and methods for preparing such cells. The invention also covers methods for using these cells to produce recombinant proteins.

Biopharmaceutical manufacturers and biotechnology companies developing protein expression systems should monitor this application for potential patent scope implications. If granted, the patent may affect production methods for recombinant proteins, including therapeutic antibodies and other biologics.

What to do next

  1. Monitor for patent grant or rejection

Archived snapshot

Apr 12, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METABOLIC SELECTION VIA THE GLYCINE-FORMATE BIOSYNTHESIS PATHWAY

Application US20260098081A1 Kind: A1 Apr 09, 2026

Inventors

Samuel Peters, James Ravellette, David Razafsky, Jason A. Gustin, Trissa Borgschulte

Abstract

The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Serine Hydroxymethyltransferase 2 (SHMT2). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.

CPC Classifications

C07K 16/00 C07K 1/14 C12N 5/0682 C12N 5/10 C12N 9/1014 C12N 9/222 C12Y 201/02001 C07K 2317/31 C12N 2510/02 C12N 2510/04

Filing Date

2023-09-29

Application No.

19112697

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260098081A1

Who this affects

Applies to
Pharmaceutical companies Clinical investigators Drug manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent applications Recombinant protein production Biologics manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!